Company intelligence / Profile preview

ICVrx

Denver, Colorado, United States

Ownership: Private
Development stage: Other

Overview

ICVrx completed preclinical work and initiated Phase 1/2 proof-of-concept clinical studies with three generic drugs reformulated for implanted pump delivery to brain sites. The approach aims to provide treatment options for medically refractory epilepsy patients by enabling site-specific drug delivery to reduce systemic toxicity and increase local drug concentrations.

Therapeutic areas: Neurology
Modalities: Device-based drug delivery systemreformulated small molecules for intracerebroventricular (ICV) delivery
Industry: Biotech

Partnerships

Epilepsy Therapy Project (investment partnership)University of Colorado (technology license)

Beyond the preview

Go deeper on ICVrx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICVrx.

Explore the full profile